Invention Grant
- Patent Title: 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
-
Application No.: US15110504Application Date: 2015-01-16
-
Publication No.: US09815813B2Publication Date: 2017-11-14
- Inventor: Zhuoliang Chen , Michael Dore , Jorge Garcia Fortanet , Rajesh Karki , Mitsunori Kato , Matthew J. LaMarche , Lawrence Blas Perez , Sarah Williams , Martin Sendzik
- Applicant: Zhuoliang Chen , Michael Dore , Jorge Garcia Fortanet , Rajesh Karki , Mitsunori Kato , Matthew J. LaMarche , Lawrence Blas Perez , Sarah Williams , Martin Sendzik
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Genomics Institute of the Novartis Research Foundation
- Agent Daniel E. Raymond
- International Application: PCT/IB2015/050344 WO 20150116
- International Announcement: WO2015/107494 WO 20150723
- Main IPC: A61K31/4427
- IPC: A61K31/4427 ; C07D401/04 ; C07D401/14 ; C07D241/26 ; C07D249/14
Abstract:
The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
Public/Granted literature
Information query
IPC分类:
